Drug-induced liver injury (DILI) is one of the most frequent reasons to stop the drug candidate optimization process (around 67% of these optimizations have been stopped for this issue), and it is the most common feature related to post-marketing withdrawals . For this reason, a current challenge is to enhance the understanding of DILI events. In this context, the current non-multidisciplinary approaches to studying hepatotoxic activity have not been exploiting and combining the large diversity of information (in silico, in vitro, in vivo, and clinical data) available to study this endpoint .